The 17.7% dilution is material for a $402M market cap biotech. Monitor for the resale registration statement filing (due ~Sep 15, 2026) and any subsequent selling by investors. The stock may face near-term pressure from the overhang of registered shares.
Price Chart
Executive Summary
Indaptus Therapeutics raised approximately $12 million through a private placement of 20 million shares at $0.60 per share to non-U.S. accredited investors, representing ~17.7% dilution relative to the ~113.2 million shares outstanding. Proceeds are earmarked for working capital, clinical development, and general corporate purposes, with registration rights granted for resale.
Key Financial Metrics
Key Facts
- 20,000,000 shares sold at $0.60/share for ~$12M gross proceeds
- Dilution of ~17.7% based on ~113.2M shares outstanding pre-offering
- Shares sold to non-U.S. accredited investors under Regulation S
- Company granted registration rights for resale; filing due within 90 days of closing
- Use of proceeds: working capital, clinical development, regulatory activities, general corporate purposes
Financial Impact
~$12M gross proceeds with ~17.7% dilution; no commissions paid
Risk Factors
- Dilution overhang from 20M new shares eligible for resale under registration rights
- Potential downward price pressure as investors may sell into the market
- Clinical-stage biotech with no revenue; cash burn may require further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-029918 |
| Document: form8-k.htm | 0001493152-26-029918 |
| Document: 0001493152-26-029918-index-headers.html | 0001493152-26-029918 |
| Document: 0001493152-26-029918-index.html | 0001493152-26-029918 |
| Document: 0001493152-26-029918.txt | 0001493152-26-029918 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access